Antihistamines are often tried, but they usually only work half the time. Dupilumab (Dupixent), a medicine that you get as a shot, is the first new treatment for CSU in the U.S. in over a decade.

In phase 3 trials, dupilumab significantly reduced itch and hives compared with placebo. The Food and Drug Administration (FDA) has approved Dupixent ® (dupilumab) for the treatment of adult and ...

Sanofi and Regeneron’s dupilumab has been given a priority review by the FDA, putting the first-in-class drug on course for a likely approval by 29 March. The drug is for adult patients with ...

Initiation rates for dupilumab and tezepelumab were similar from 2022 to 2023. Dupilumab and tezepelumab work best with high eosinophil levels. Trends were similar at the study site and patient ...

has approved Dupixent ® (dupilumab) for the treatment of adults and adolescents aged 12 years and older with chronic spontaneous urticaria (CSU) who remain symptomatic despite histamine-1 (H1 ...

Sanofi and Regeneron's fully human monoclonal antibody Dupixent (dupilumab) has gained approval from the US Food and Drug Administration (FDA) for treating chronic spontaneous urticaria (CSU ...

Abrocitinib demonstrates superior efficacy over dupilumab and placebo in achieving stringent clinical outcomes, including EASI-90 and complete skin clearance, in moderate to severe atopic dermatitis.

The US Food and Drug Administration (FDA) has approved dupilumab for the treatment of chronic spontaneous urticaria (CSU) in patients aged 12 years and older who “remain symptomatic despite H1 ...

Please provide your email address to receive an email when new articles are posted on . Dupilumab was approved for treatment of chronic spontaneous urticaria in patients aged 12 years and older.